SCHEMBL4785121

SCHEMBL4785121

CC1CN(S(=O)(=O)c2ccc(Sc3cccc4cccnc34)c3nonc23)CC(C)O1

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.54
GFER P55789 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.43
KCNT2 Q6UVM3 1/20 0.42
ALOX15 P16050 2/20 0.40
ALDH1A1 P00352 6/20 0.40
HTT P42858 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
HPGD P15428 2/20 0.40
LMNA P02545 2/20 0.39
RECQL P46063 1/20 0.39
GAA P10253 2/20 0.39
POLB P06746 1/20 0.39
KDM4E B2RXH2 1/20 0.38
GLA P06280 1/20 0.38
HSD17B10 Q99714 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4784036 0.91 TSHR (0.67) TSHRGFERL3MBTL1KCNT2ALOX15
SCHEMBL4787717 0.86 TSHR (0.42) TSHRGFERL3MBTL1KCNT2ALOX15
SCHEMBL5244145 0.84 L3MBTL1 (0.50) TSHRGFERL3MBTL1ALOX15ALDH1A1
SCHEMBL4787718 0.84 TSHR (0.41) TSHRGFERL3MBTL1ALDH1A1HTT
SCHEMBL4787514 0.84 L3MBTL1 (0.52) TSHRGFERL3MBTL1ALOX15ALDH1A1
SCHEMBL4786255 0.82 L3MBTL1 (0.48) TSHRGFERL3MBTL1ALOX15ALDH1A1
SCHEMBL4743057 0.81 ALDH1A1 (0.47) TSHRALDH1A1HTTSMN1; SMN2LMNA
SCHEMBL5242720 0.80 ALDH1A1 (0.67) TSHRL3MBTL1ALOX15ALDH1A1HTT
SCHEMBL5242949 0.79 ALDH1A1 (0.53) TSHRGFERL3MBTL1ALOX15ALDH1A1
SCHEMBL4745387 0.78 TSHR (0.51) TSHRGFERALDH1A1HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO claimed
EP-1758873-A1 UBIQUITIN LIGASE INHIBITORS Rigel Pharmaceuticals, Inc. (US) 2007-03-07 EP claimed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO claimed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US claimed
WO-2008115259-A2 DERIVATIVES OF BENZOXADIAZOLE SUITABLE FOR THE TREATMENT OF CELL PROLIFERATIVE DISEASES RIGEL PHARMACEUTICALS, INC. (US) 2008-09-25 WO disclosed
WO-2006002284-A1 UBIQUITIN LIGASE INHIBITORS RIGEL PHARMACEUTICALS, INC. (US) 2006-01-05 WO disclosed
US-20050282818-A1 Ubiquitin ligase inhibitors RIGEL PHARMACEUTICALS, INC. (US) 2005-12-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050282818-A1 Ubiquitin ligase inhibitors NEDD4, TRAF6, XIAP TSHR 4795/4885GFER 2796/4885L3MBTL1 2603/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.